This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Tue May 21, 2013 3:22 pm


All times are UTC - 8 hours [ DST ]




Post new topic Reply to topic  [ 2 posts ] 
Author Message
PostPosted: Thu May 03, 2012 4:50 pm 
Offline
Getting to Know You...

Joined: Thu Oct 06, 2011 4:02 pm
Posts: 10
Phase IIb to start late June/early July and will be called Abili-t. Visit Abili-t.com


Top
 Profile  
 
PostPosted: Mon May 07, 2012 9:20 am 
Offline
Family Elder

Joined: Sat Sep 15, 2007 3:00 pm
Posts: 105
Location: Chicago, IL
As a former IIb trial participant who believes in the medication, I hope that they get it approved somehow, some way. If going the progressive MS route is the way to go, then I'm for it. Obviously, folks saddled with that disease progression also need all the help that they can get. I assume this is a way for Opexa to avoid the pitfalls of the last trial. Getting "sicker" patients in will likely more clearly delineate effectiveness in the vaccine arm vs. placebo arm.

I'll be watching and hoping and pulling for the trial participants as well. Good luck and thanks, gang, whoever you turn out to be. :smile:


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

All times are UTC - 8 hours [ DST ]


Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. TCELNA 11B trial will start recruiting for the Abili-T trial

reallyreally

0

602

Wed Sep 12, 2012 12:29 pm

reallyreally View the latest post

 


Who is online

Users browsing this forum: No registered users


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: